Previous close | 20.87 |
Open | 20.87 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 20.87 - 20.87 |
52-week range | 20.87 - 28.73 |
Volume | |
Avg. volume | 460 |
Market cap | 11.217B |
Beta (5Y monthly) | 0.11 |
PE ratio (TTM) | 26.02 |
EPS (TTM) | 0.80 |
Earnings date | N/A |
Forward dividend & yield | 0.41 (1.84%) |
Ex-dividend date | 29 Jun 2023 |
1y target est | N/A |
SAN DIEGO & TOKYO, December 05, 2022--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that after receiving the most recent guidance from a late November meeting with the U.S. Food and Drug Administration (FDA), the companies are discontinuing glob
AACHEN, Germany & TOKYO, November 24, 2022--Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company, are today announcing they have signed a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio. The Joint Venture Collaboration comprises 13 brands across 6 therapeutic
SAN DIEGO & TOKYO, November 03, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that three abstracts highlighting data and information from the clinical development program evaluating the intermittent dosing of zandelisib, an investigational